Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Wockhardt Limited - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Wockhardt Limited - Product Pipeline Review - 2015', provides an overview of the Wockhardt Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Wockhardt Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Wockhardt Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Wockhardt Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Wockhardt Limited's pipeline products Reasons To Buy - Evaluate Wockhardt Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Wockhardt Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Wockhardt Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Wockhardt Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Wockhardt Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Wockhardt Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Wockhardt Limited Snapshot 5 Wockhardt Limited Overview 5 Key Information 5 Key Facts 5 Wockhardt Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Wockhardt Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Wockhardt Limited - Pipeline Products Glance 11 Wockhardt Limited - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Wockhardt Limited - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Wockhardt Limited - Drug Profiles 14 WCK-2349 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 WCK-771 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 tenatoprazole 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 WCK-4873 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 zidebactam 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 WCK-4086 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Wockhardt Limited - Pipeline Analysis 22 Wockhardt Limited - Pipeline Products by Target 22 Wockhardt Limited - Pipeline Products by Route of Administration 23 Wockhardt Limited - Pipeline Products by Molecule Type 24 Wockhardt Limited - Pipeline Products by Mechanism of Action 25 Wockhardt Limited - Recent Pipeline Updates 26 Wockhardt Limited - Dormant Projects 27 Wockhardt Limited - Locations And Subsidiaries 28 Head Office 28 Other Locations & Subsidiaries 28 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Wockhardt Limited, Key Information 5 Wockhardt Limited, Key Facts 5 Wockhardt Limited - Pipeline by Indication, 2015 8 Wockhardt Limited - Pipeline by Stage of Development, 2015 9 Wockhardt Limited - Monotherapy Products in Pipeline, 2015 10 Wockhardt Limited - Phase II, 2015 11 Wockhardt Limited - Phase I, 2015 12 Wockhardt Limited - Preclinical, 2015 13 Wockhardt Limited - Pipeline by Target, 2015 22 Wockhardt Limited - Pipeline by Route of Administration, 2015 23 Wockhardt Limited - Pipeline by Molecule Type, 2015 24 Wockhardt Limited - Pipeline Products by Mechanism of Action, 2015 25 Wockhardt Limited - Recent Pipeline Updates, 2015 26 Wockhardt Limited - Dormant Developmental Projects,2015 27 Wockhardt Limited, Other Locations 28 Wockhardt Limited, Subsidiaries 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.